Simvastatin Improves Flow-Mediated Dilation but Reduces Adiponectin Levels and Insulin Sensitivity in Hypercholesterolemic Patients

Abstract

OBJECTIVE -We hypothesized that simvastatin may reduce adiponectin levels and insulin sensitivity in hypercholesterolemic patients.RESEARCH DESIGN AND METHODS -This was a randomized, double-blind, placebo-controlled, parallel study. Age, sex, and BMI were matched. Thirty-two patients were given placebo, and 30, 32, 31, and 31 patients were given daily 10, 20, 40, and 80 mg simvastatin, respectively, during a 2-month treatment period.RESULTS -Simvastatin doses of 10, 20, 40, and 80 mg significantly reduced total cholesterol (mean changes 27, 25, 37, and 38%), LDL cholesterol (39, 38, 52, and 54%), and apolipoprotein B levels (24, 30, 36, and 42%) and improved flow-mediated dilation (FMD) (68, 40, 49, and 63%) after 2 months of therapy compared with baseline (P Ͻ 0.001 by paired t test) or compared with placebo (P Ͻ 0.001 by ANOVA). Simvastatin doses of 10, 20, 40, and 80 mg significantly decreased plasma adiponectin levels (4, 12, 5, and 10%) and insulin sensitivity (determined by the Quantitative Insulin-Sensitivity Check Index [QUICKI]) (5,8,6, and 6%) compared with baseline (P Ͻ 0.05 by paired t test) or compared with placebo (P ϭ 0.011 for adiponectin and P ϭ 0.034 for QUICKI by ANOVA). However, the magnitudes of these percent changes (FMD, adiponectin, and QUICKI) were not significantly different among four different doses of simvastatin despite dose-dependent changes in the reduction of apolipoprotein B levels.CONCLUSIONS -Simvastatin significantly improved endothelium-dependent dilation, but reduced adiponectin levels and insulin sensitivity in hypercholesterolemic patients independent of dose and the extent of apolipoprotein B reduction. Diabetes Care 31:776-782, 2008

The effect of different doses of vitamin D3 on markers of vascular health in patients with type 2 diabetes: a randomised controlled trial

“…Exercise training and statin therapy (which are known to reduce the risk of cardiovascular events) have been shown to produce an improvement of at least 2% in brachial artery FMD [18,19]. To detect this change with 80% power, assuming a standard deviation of change of 3% as found in our previous work [2] and alpha=0.05, requires 27 participants per group.…”

Molecular Mechanisms of HDL-Cholesterol Elevation by Statins and Its Effects on HDL Functions

“…Pitavastatin and pravastatin elevate adiponectin expression in adipocytes 80) . Clinically, the adiponectin-elevating effects differ among statins [81][82][83][84] , and pitavastatin reportedly increases adiponectin levels in hyperlipidemic patients with diabetes mellitus. Suppression of reactive oxygen species (ROS) production, and activation of SREBP1c and PPAR have been proposed as possible mechanisms 85) .…”

Statins and Renin-Angiotensin System Inhibitor Combination Treatment to Prevent Cardiovascular Disease

“…44 levels and insulin sensitivity in hypercholesterolemic patients. 42 In a comparison study of simvastatin and pravastatin, simvastatin (20 mg) significantly increased fasting insulin levels and decreased plasma adiponectin levels and insulin sensitivity, whereas pravastatin (40 mg) treatment did not significantly change insulin levels but significantly increased plasma adiponectin levels and insulin sensitivity at equivalent lipid- Figure 4. Synergistic effect of statins and renin-angiotensin system (RAS) inhibitors on insulin sensitivity.…”